COST EFFECTIVENESS OF AN OUTCOME BASED REIMBURSEMENT MODEL OF PCSK9 INHIBITORS

COST EFFECTIVENESS OF AN OUTCOME BASED REIMBURSEMENT MODEL OF PCSK9 INHIBITORS

Four separate outcome-based reimbursement thresholds (three LDL levels; occurrence of a cardiovascular event) were used to compute adjusted ICERs, which were compared to that of atorvastatin. For an outcome-based reimbursement model that compensates patients based on a cardiovascular end-point (card...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A1753-A1753
Hauptverfasser: Oren, Ohad, Oren, Michal
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cost effectiveness
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Four separate outcome-based reimbursement thresholds (three LDL levels; occurrence of a cardiovascular event) were used to compute adjusted ICERs, which were compared to that of atorvastatin. For an outcome-based reimbursement model that compensates patients based on a cardiovascular end-point (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization), the adjusted ICER was calculated at 246.0K/QALY.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)32294-0